Literature DB >> 30957991

Drug Delivery Strategies for the Treatment of Metabolic Diseases.

Sanjun Shi1, Na Kong1, Chan Feng1, Aram Shajii1, Claire Bejgrowicz1, Wei Tao1, Omid C Farokhzad1.   

Abstract

Metabolic diseases occur when normal metabolic processes are disrupted in the human body, which can be congenital or acquired. The incidence of metabolic diseases worldwide has reached epidemic proportions. So far, various methods including systemic drug therapy and surgery are exploited to prevent and treat metabolic diseases. However, current pharmacotherapeutic options for treatment of these metabolic disorders remain limited and ineffective, especially reducing patient compliance to treatment. Therefore, it is desirable to exploit effective drug delivery approaches to effectively treat metabolic diseases and reduce side effects. This brief review summarizes novel delivery strategies including local, targeted, and oral drug delivery strategies, as well as intelligent stimulus-responsive drug delivery strategy, for the treatment of metabolic disorders including diabetes, obesity, and atherosclerosis.
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  biomaterials; drug delivery; metabolic diseases; nanomedicine

Year:  2019        PMID: 30957991      PMCID: PMC6663576          DOI: 10.1002/adhm.201801655

Source DB:  PubMed          Journal:  Adv Healthc Mater        ISSN: 2192-2640            Impact factor:   9.933


  65 in total

1.  Nanosphere based oral insulin delivery.

Authors:  G P Carino; J S Jacob; E Mathiowitz
Journal:  J Control Release       Date:  2000-03-01       Impact factor: 9.776

Review 2.  Use of targeting agents to increase uptake and localization of drugs to the intestinal epithelium.

Authors:  G J Russell-Jones
Journal:  J Drug Target       Date:  2004-02       Impact factor: 5.121

3.  Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin.

Authors:  Na Zhang; Qineng Ping; Guihua Huang; Wenfang Xu; Yanna Cheng; Xiuzhen Han
Journal:  Int J Pharm       Date:  2006-07-21       Impact factor: 5.875

4.  De novo adipose tissue generation through long-term, local delivery of insulin and insulin-like growth factor-1 by PLGA/PEG microspheres in an in vivo rat model: a novel concept and capability.

Authors:  E Yuksel; A B Weinfeld; R Cleek; J M Waugh; J Jensen; S Boutros; S M Shenaq; M Spira
Journal:  Plast Reconstr Surg       Date:  2000-04       Impact factor: 4.730

Review 5.  Leptin resistance and obesity.

Authors:  Pablo J Enriori; Anne E Evans; Puspha Sinnayah; Michael A Cowley
Journal:  Obesity (Silver Spring)       Date:  2006-08       Impact factor: 5.002

6.  Glucose-responsive UV polymerised dextran-concanavalin A acrylic derivatised mixtures for closed-loop insulin delivery.

Authors:  Sangeeta Tanna; M Joan Taylor; Tarsem S Sahota; Kirsty Sawicka
Journal:  Biomaterials       Date:  2005-09-02       Impact factor: 12.479

7.  Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats.

Authors:  Christiane Damgé; Philippe Maincent; Nathalie Ubrich
Journal:  J Control Release       Date:  2006-10-25       Impact factor: 9.776

Review 8.  The obesity pipeline: current strategies in the development of anti-obesity drugs.

Authors:  Dunstan Cooke; Steve Bloom
Journal:  Nat Rev Drug Discov       Date:  2006-11       Impact factor: 84.694

Review 9.  Leptin and atherosclerosis.

Authors:  Jerzy Beltowski
Journal:  Atherosclerosis       Date:  2006-04-03       Impact factor: 5.162

10.  Adipose tissue mass can be regulated through the vasculature.

Authors:  Maria A Rupnick; Dipak Panigrahy; Chen-Yu Zhang; Susan M Dallabrida; Bradford B Lowell; Robert Langer; M Judah Folkman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

View more
  10 in total

1.  Orally Administrable Therapeutic Synthetic Nanoparticle for Zika Virus.

Authors:  Bapurao Surnar; Mohammad Z Kamran; Anuj S Shah; Uttara Basu; Nagesh Kolishetti; Sapna Deo; Dushyantha T Jayaweera; Sylvia Daunert; Shanta Dhar
Journal:  ACS Nano       Date:  2019-10-11       Impact factor: 15.881

Review 2.  Surface-modified nanotherapeutics targeting atherosclerosis.

Authors:  Wenpan Li; Karina Marie Gonzalez; Jinha Chung; Minhyeok Kim; Jianqin Lu
Journal:  Biomater Sci       Date:  2022-09-27       Impact factor: 7.590

3.  Reducing Effect of Farnesylquinone on Lipid Mass in C. elegans by Modulating Lipid Metabolism.

Authors:  Xihua Jia; Manglin Xu; Aigang Yang; Yan Zhao; Dong Liu; Jian Huang; Peter Proksch; Wenhan Lin
Journal:  Mar Drugs       Date:  2019-06-05       Impact factor: 5.118

Review 4.  Two-Dimensional Nanosheet-Based Photonic Nanomedicine for Combined Gene and Photothermal Therapy.

Authors:  Na Yoon Kim; Sara Blake; Diba De; Jiang Ouyang; Jinjun Shi; Na Kong
Journal:  Front Pharmacol       Date:  2020-01-21       Impact factor: 5.810

Review 5.  Deep Eutectic Solvents as Active Pharmaceutical Ingredient Delivery Systems in the Treatment of Metabolic Related Diseases.

Authors:  Cixin Huang; Xiunian Chen; Chao Wei; Hongwei Wang; Hua Gao
Journal:  Front Pharmacol       Date:  2021-12-24       Impact factor: 5.810

6.  Analysis on the Effect of Metformin Hydrochloride Combined with Insulin Pump for Gestational Diabetes Mellitus.

Authors:  Xinghua Li; Guilian Li; Yan Liu; Fanchun Meng; Lihong Han; Yuanyuan Shao
Journal:  Iran J Public Health       Date:  2022-01       Impact factor: 1.429

7.  Multi-functional self-assembly nanoparticles originating from small molecule natural product for oral insulin delivery through modulating tight junctions.

Authors:  Xiaohui Jia; Zhihua Yuan; Yuqin Yang; Xuemei Huang; Nana Han; Xiaojing Liu; Xiaoyu Lin; Tao Ma; Bing Xu; Penglong Wang; Haimin Lei
Journal:  J Nanobiotechnology       Date:  2022-03-05       Impact factor: 10.435

8.  The efficacy and safety of Laminaria japonica for metabolic syndrome: A protocol for systematic review.

Authors:  Bonglee Kim; In-Seon Lee; Seok-Jae Ko
Journal:  Medicine (Baltimore)       Date:  2022-02-18       Impact factor: 1.817

9.  Tumor pH-responsive metastable-phase manganese sulfide nanotheranostics for traceable hydrogen sulfide gas therapy primed chemodynamic therapy.

Authors:  Ting He; Xialing Qin; Chao Jiang; Dawei Jiang; Shan Lei; Jing Lin; Wei-Guo Zhu; Junle Qu; Peng Huang
Journal:  Theranostics       Date:  2020-01-20       Impact factor: 11.556

Review 10.  RNA N6-methyladenosine: a promising molecular target in metabolic diseases.

Authors:  Huakui Zhan; Keyang Xu; Yan Li; Jiawen Wang; Chunyan Huang; Meng Shen
Journal:  Cell Biosci       Date:  2020-02-21       Impact factor: 7.133

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.